IP: Dra. Rocío I. Rodríguez Macías

Resumen del proyecto: As part of a broader project aimed at identifying new biomarkers that allow a differential diagnosis between the two main types of hepatic tumors: hepatocarcinoma (HCC) and cholangiocarcinoma (CCA), one of the objectives of this Project is to determine the metabolomic profile in serum samples of patients with HCC, CCA and healthy subjects, as well as in primary sclerosing cholangitis (PSC), considered one of the main risk factors to develop CCA. To this end, the metabolomic profile will be determined by liquid chromatography-mass spectrometry (UHPLC/MS) in three platforms (polars, lipids, and aminoacids). In particular, the service includes the extraction, measurementand analysis of metabolites (bile acids, non esterified fatty acids, phospholipids, sterols, sphingolipids, glycerolipids, etc) in serum samples of patients with CCA, HCC, PSC and controls, and development of statistical evaluations among groups. Metabolomic analyses will be carried out by One Way Liver S.L. (OWL), a biotechnology company in the field of metabolomics with pioneering diagnostics products and unique R&D services for the scientific community, and the conditions have already been established. The aim is to identify specific biomarkers that allow a differential diagnosis between both types of hepatic tumors and between PSC and CCA. It is envisaged to request serum samples to the Biobanks Network DNA National Bank Carlos III (University of Salamanca), and to the following biobanks of other hospitals and institutes, with researches in charge: Clínica Universitaria de Navarra (Dr. Bruno Sangro), Hospital Universitario Virgen del Rocío de Sevilla (Dr. Jordi Muntané), Instituto de Biodonostia de San Sebastián (Dr. Jesús Bañales). We aim to achieve about 40-50.

Entidad financiadora: Centro de Investigación Biomédica en Red para el estudio de enfermedades hepáticas y digestivas (CIBERehd)